This clinical trial is focused on studying treatments for estrogen receptor (ER)-positive HER2-negative breast cancer in women over the age of 70. The study is exploring the effects of combining chemotherapy with hormone therapy compared to hormone therapy alone. The chemotherapy drugs being used in this study include cyclophosphamide, doxorubicin, and docetaxel. These medications are administered through an intravenous (IV) route, which means they are given directly into a vein.
The purpose of the study is to evaluate the benefit of adding chemotherapy to the treatment plan for elderly patients who have a high risk of cancer returning, as determined by a specific test called the Genomic Grade (GG). Participants in the study will receive treatment over a period of up to 12 months. The study will follow participants for four years to assess their overall survival, which means the length of time they live after starting the treatment. Other aspects being evaluated include the quality of life and any side effects experienced during the treatment.
This trial is part of a larger effort by the French UNICANCER Geriatric Oncology Group and Breast Group to improve treatment options for older women with this type of breast cancer. The study aims to provide valuable information on how effective the combination of chemotherapy and hormone therapy is in improving survival rates and quality of life for these patients. Participants will be closely monitored throughout the study to ensure their safety and well-being.
Belgium 
France 
